Loading
companiesCompany
Novocure
Novocure makes Optune tumour treating fields, approved in glioblastoma, lung, mesothelioma, and (2026) pancreatic cancer.
Overview
Novocure, based in Root, Switzerland, and listed as NVCR, makes Optune tumour treating fields, approved in glioblastoma, lung cancer, mesothelioma and, in 2026, pancreatic cancer. Its devices are Optune Gio, Optune Lua and Optune Pax, with EF-14 in glioblastoma and PANOVA-3 in pancreatic cancer as the pivotal trials linked, and trials continue in brain metastases and gastric cancer; Zai Lab is its partner in China. OnCo links it to glioma, mesothelioma and pancreatic ductal adenocarcinoma, to the tumour treating fields technology, to the Lurie and Zurich cancer centres, and to the brain as a bottleneck. Whether clinicians adopt a device therapy as readily as a drug is the open question. Optune has its own page.
Headquarters
Root, CH
Scorecard
All companies#209of 1244 companies, score 26
- approved products +6
- modalities +2
- regions +4
- 24-month regulatory events +4
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 0 targets, 24 registry studies. Formula on the scorecards page.
Type
Devices & RT hardware · NVCR
Stage
Public
Website
ApprovedDevice (tumour treating fields)
Optune / Optune Pax (TTFields) · Optune
Optune is a wearable device delivering electric fields that disrupt cell division. It is approved for glioblastoma and, in 2026, pancreatic cancer.
Similar pages
- PersonRoger Stupp
Shares EF-14, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- Key paperLAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine
Shares Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
- TrialLAP07
Shares PANOVA-3, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
- PersonHedy L. Kindler
Shares Mesothelioma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
- TrialA Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- TrialCONKO-007
Shares PANOVA-3, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- PersonRolf A. Stahel
Shares University Hospital Zurich / Comprehensive Cancer Center Zurich, Mesothelioma.
- CompanyAlpha Tau Medical
Shares Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
cancers
fronts
technologies
drugs
ApprovedDevice (tumour treating fields)
Optune / Optune Pax (TTFields) · Optune